Jounce Story

<div class='circular--portrait' style='background:#169D0B;color: #E6E6FA;font-size:4em;'>JT</div>
JNCE -- USA Stock  

USD 7.96  0.77  8.82%

As many millenniums are trying to avoid healthcare space, it makes sense to digest Jounce Therapeutics a little further and try to understand its current market patterns. Why are we still confident in anticipation of a complete recovery. What is the firm valuation so far in 2020? We are going to cover Jounce Therapeutics perspective on valuation to give investors a better transparency on taking a position in it.
Published over a month ago
View all stories for Jounce Therapeutics | View All Stories
Should you drop Jounce Therapeutics (NASDAQ:JNCE) based on its latest valuation?
This firm currently holds 19.1 M in liabilities with Debt to Equity (D/E) ratio of 0.13, which may suggest Jounce Therapeutics is not taking enough advantage from borrowing. The company has a current ratio of 10.45, suggesting that it is liquid enough and is able to pay its financial obligations when due. Jounce Therapeutics has performance score of 1 on a scale of 0 to 100. The company retains a Market Volatility (i.e. Beta) of 0.9791, which attests to possible diversification benefits within a given portfolio. Let's try to break down what Jounce's beta means in this case. Jounce Therapeutics returns are very sensitive to returns on the market. As the market goes up or down, Jounce Therapeutics is expected to follow. Although it is extremely important to respect Jounce Therapeutics current price history, it is better to be realistic regarding the information on equity current price movements. The philosophy towards determining future performance of any stock is to evaluate the business as a whole together with its past performance, including all available fundamental and technical indicators. By evaluating Jounce Therapeutics technical indicators, you can presently evaluate if the expected return of 0.0788% will be sustainable into the future. Jounce Therapeutics right now retains a risk of 4.83%. Please check out Jounce Therapeutics maximum drawdown, as well as the relationship between the downside variance and skewness to decide if Jounce Therapeutics will be following its current trending patterns.
We determine the current worth of Jounce Therapeutics using both absolute as well as relative valuation methodologies to arrive at its intrinsic value. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Jounce Therapeutics based exclusively on its fundamental and basic technical indicators. By analyzing Jounce Therapeutics's financials, quarterly and monthly indicators, and related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Jounce Therapeutics's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Jounce Therapeutics. We calculate exposure to Jounce Therapeutics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Jounce Therapeutics's related companies.

Jounce Therapeutics Investment Alerts

Jounce investment alerts and warnings help investors to get more proficient at understanding not only critical technical and fundamental signals but also the significant portfolio-centered indicators. These indicators include beta, alpha, and other risk-related measures that will help you in monitoring Jounce Therapeutics performance across your portfolios.Please check all investment alerts for Jounce

Jounce Therapeutics Valuation Ratios as Compared to Competition

Our valuation model uses many indicators to compare Jounce value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Jounce Therapeutics competition to find correlations between indicators driving the intrinsic value of Jounce.

How Jounce utilizes its cash?

To perform a cash flow analysis of Jounce Therapeutics, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Jounce Therapeutics is receiving and how much cash it distributes out in a given period. The Jounce Therapeutics cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Jounce Therapeutics Net Cash Flow from Operations is projected to decrease significantly based on the last few years of reporting. The past year's Net Cash Flow from Operations was at (30.13 Million)

Is Jounce Therapeutics valued correctly by the market?

Jounce Therapeutics reported the previous year's revenue of 136.89 M. Net Income was 42.76 M with profit before overhead, payroll, taxes, and interest of 122 M.
 2010 2019 2020 (projected)
Calculated Tax Rate0.08090.07280.0724
Interest Coverage6.96.216.17

Margins Breakdown

Jounce profit margins show the degree to which it makes money. Margin indicators are used not only by investors but also by creditors or Jounce Therapeutics itself as indicators of financial health and management effectiveness. Please look more closely at the different varieties of Jounce Therapeutics profit margins.
Operating Margin38.54
EBITDA Margin0.44
Gross Margin0.89
Profit Margin0.41


Jounce Therapeutics Earnings Before Interest Taxes and Depreciation Amortization EBITDA is increasing over the last 7 years. Further, Jounce Therapeutics Revenue Per Employee is rather stable at the moment. Jounce Therapeutics Earnings Before Interest Taxes and Depreciation Amortization EBITDA is increasing over the last 7 years. The latest value of Jounce Therapeutics Earnings Before Interest Taxes and Depreciation Amortization EBITDA is 65,513,684. Further, Jounce Therapeutics Revenue Per Employee is increasing over the last 5 years. The latest value of Jounce Therapeutics Revenue Per Employee is 1,227,278.

Will Jounce Therapeutics latest surge continue?

Latest Treynor Ratio is up to -0.06. Price may dip again. Jounce Therapeutics exhibits very low volatility with skewness of -0.06 and kurtosis of 0.74. However, we advise investors to further study Jounce Therapeutics technical indicators to make sure all market info is available and is reliable.

Our Final Takeaway

Although other entities under the biotechnology industry are still a bit expensive, Jounce Therapeutics may offer a potential longer-term growth to shareholders. The inconsistency in the assessment between current Jounce valuation and our trade advice on Jounce Therapeutics is due to the recent market swings and your selection of investing horizon. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Jounce Therapeutics.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Achuva Shats do not own shares of Jounce Therapeutics. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com